| 0 (0%) | 01-19 18:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 81.63 |
1-year : | 95.34 |
| Resists | First : | 69.88 |
Second : | 81.63 |
| Pivot price | 67.66 |
|||
| Supports | First : | 66.62 |
Second : | 64.61 |
| MAs | MA(5) : | 68.81 |
MA(20) : | 67.3 |
| MA(100) : | 63.16 |
MA(250) : | 56.56 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 84.7  |
D(3) : | 86.7 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 69.88 | Low : | 45.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MMP ] has closed below upper band by 23.7%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 69.97 - 70.25 | 70.25 - 70.49 |
| Low: | 68.03 - 68.37 | 68.37 - 68.67 |
| Close: | 68.41 - 68.97 | 68.97 - 69.45 |
Mon, 19 Jan 2026
MBDA Delivers 1000th MMP Missile to the French Ministry of the Armed Forces - Defence Turkey Magazine
Mon, 19 Jan 2026
Zincure synthesizes new MMP-9 inhibitors - BioWorld MedTech
Wed, 14 Jan 2026
MMP Capital Marks Record Year and Accelerates Growth with New Facilities and NY Expansion - MonitorDaily
Sun, 11 Jan 2026
MMP D33-455F-36V GP81-068 brushed DC gearmotor introduced - Design World
Thu, 08 Jan 2026
Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC - Yahoo Finance
Thu, 08 Jan 2026
Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi's potential - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 202 (M) |
| Shares Float | 201 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 53 (%) |
| Shares Short | 7,310 (K) |
| Shares Short P.Month | 5,410 (K) |
| EPS | 5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.47 |
| Profit Margin | 29.5 % |
| Operating Margin | 32.5 % |
| Return on Assets (ttm) | 9.1 % |
| Return on Equity (ttm) | 59.1 % |
| Qtrly Rev. Growth | 11.1 % |
| Gross Profit (p.s.) | 7.37 |
| Sales Per Share | 17.21 |
| EBITDA (p.s.) | 7.02 |
| Qtrly Earnings Growth | -29.8 % |
| Operating Cash Flow | 1,500 (M) |
| Levered Free Cash Flow | 760 (M) |
| PE Ratio | 13.8 |
| PEG Ratio | 3.9 |
| Price to Book value | 8.13 |
| Price to Sales | 4 |
| Price to Cash Flow | 9.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|